Clinical Trial Update: Efficacy and Safety of SPD417 in Treatment of Manic Symptoms in Adults With Bipolar I Disorder [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SPD417 for manic symptoms in adults with Bipolar I Disorder has completed, assessing efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• SPD417 (SPD417)

Snippet

Sponsor: Validus Pharmaceuticals | Conditions: Bipolar Disorder | Phase 3 | Status: COMPLETED